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ABSTRACT  
Background: Although having a long tradition in cardiovascular epidemiologic research, nationwide data 
on cardiovascular disease (CVD) incidence and morbidity has not been available in Norway. 
Objectives: The main objectives of The Cardiovascular Disease in Norway (CVDNOR) project are 1) to 
study trends in CVD incidence, prevalence, survival and mortality and 2) providing CVD endpoints for 
national and regional health surveys and clinical studies. 
Methods: CVDNOR includes information from all hospital stays with a CVD, including congenital heart 
defects, or diabetes mellitus (DM) primary or secondary diagnosis code during 1994-2009. Information 
was retrieved from the electronic Patient Administrative Systems (PAS) from all Norwegian somatic hospi-
tals. Data include age, gender, municipality of residence, hospitalization and discharge dates, main and 
secondary diagnoses and CVD-related procedure codes. All deaths due to CVD or DM are also included, 
as well as sociodemographic information and linkage to Cohort Norway (CONOR). In sub-projects we 
have also linked CVDNOR to the Medical Birth Registry of Norway and to the Cancer Registry. 
Results: During 1994-2009, 1.3 million patients (4.3 mill hospitalizations) had a CVD diagnosis or pro-
cedure code, or DM. Of these, 470895 (35.8%) died during 1994-2010. In addition, 68523 men and women 
died from CVD without being hospitalized for CVD or DM during the same period. Among 173243 
CONOR participants, 9075 (5%) died after participating in the health survey and through 2010. A total of 
44118 (25.5%) CONOR participants had a CVD and 7575 (4.4%) had a DM related hospitalization after 
participating in CONOR, through 2009. In CVDNOR, 53039 (4%) had congenital heart defect codes. 
Conclusions: CVDNOR will be a valuable source of information supporting future epidemiologic research, 
with important implications for prevention and treatment strategies. 
 
 
INTRODUCTION 
 
During the last decades, cardiovascular disease morta-
lity has decreased substantially in Norway [1,2] as in 
other Scandinavian and western European countries 
[3-5]. The changes have not been uniform across all 
sex and age groups [1]. While mortality trends are 
known in Norway, there is lack of information on 
trends in incidence and survival. Norway did not have, 
until 2012, a national register on cardiovascular disease 
(CVD). This has hampered studies of incidence and 
survival as well as aetiologic research nationwide. 
 The Norwegian Patient Register, containing infor-
mation on all patients hospitalized at Norwegian hos-
pitals since 1990, has the potential to overestimate the 
true number of hospitalizations and cannot provide 
information on incidence, due to the lack of person-
identifiable information until 2008. Several regional 
studies have published important information on risk 
factors [6-8] and occurrence of CVD [9-12]. Never-
theless, as shown by the WHO MONICA project, there 
is a non-negligible difference in occurrence and risk 
factors for CVD between and even within countries 
[13,14]. Therefore, findings from regional studies may 
not be generalizable to the general Norwegian popu-
lation. To fill this gap of knowledge on one of the most 
important sources of morbidity and mortality in the 
Norwegian population and elsewhere, the CVDNOR 
project was planned. 
 
 
CVDNOR – A PROJECT OFFERING NEW 
RESEARCH OPPORTUNITIES 
 
The Cardiovascular Disease in Norway (CVDNOR) 
project began as a collaborative research project 
between the University of Bergen and the Norwegian 
Knowledge Centre for the Health Services. It is a po-
pulation study with major focus on CVD and DM. The 
two main objectives are:  
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Table 1.  Diagnoses and procedures in CVDNOR 1994-2009. 
 
Diagnoses included in CVDNOR ICD9 (1994-1998) ICD10 (1999-2009) 
Diseases of the circulatory system 390-459 I00-I99 
Oedema, proteinuria and hypertensive complications during pregnancy and childbirth 642 O10-O16 
Diabetes mellitus during pregnancy 648.0 O24 
Transient cerebral ischemic attacks and related syndromes 435 G 45 
Diabetes mellitus 250 E10-E14 
Non-diabetic hypoglycaemic coma 251.0 E15 
Sudden, unexpected death 798.1 R96 
Congenital malformations of the circulatory system 745-747 Q20-Q28 
Main diagnostic and treatment procedures SIF95 ± NCMP┼ and NCSP ¶ 
Interventions in the heart and great vessels 3000-3299 FA-FY 
Coronary angiography/left-sided catheterization 3291, 3235*, 3238* FYDB,TFC10, XF911, 
XF912, XF914 
Right-sided catheterization 3290 TFC00 
Electrophysiologic study/intervention of the heart 3292 FPA, FPB, FPFE 
Transthoracic/transesophageal echocardiogram 3293 FYDE 
Percutaneous coronary intervention (PCI) 3294, 3236*, 3239* FNG 
Coronary artery bypass grafting (CABG) 3112-3129 FNA-FNF 
Pacemaker/defibrillator implantation procedures 3200-3209 FPE, FPF, FPG 
Interventions on peripheral blood vessels and lymphatic system 8800-8899 PA-PY 
* Local codes used by University hospitals Haukeland and Stavanger. 
± Norwegian classification of medical procedures; 3rd edition, 1995. 
┼ Norwegian classification of medical procedures. 
¶ The NOMESCO classification of surgical procedures; NCMP and NCSP were brought together in 2006 [20]. 
 
 
 
1. to study trends in CVD incident and recurrent events, 
short and long term prognosis (survival) and associ-
ated factors in the total Norwegian population, 
2. to provide CVD and DM endpoints for national and 
regional health surveys conducted during the last 
decades in Norway, as well as for clinical studies. 
CVDNOR will facilitate studies of the impact of se-
veral known and potential risk factors (alone and in 
combination, as well as of changes in risk factors) in 
CVD occurrence. 
 
Data collection and quality control 
 
Hospital data 
Hospital stays with a CVD (ICD9: 390-459, ICD10: 
I00-I99, G45), DM (ICD9: 250, ICD10: E10-E14) or 
congenital malformations of the circulatory system 
(ICD9: 745-747, ICD10: Q20-Q28) as either primary 
or secondary diagnosis, as well as all related proce-
dures, were retrieved from the electronic Patient Ad-
ministrative Systems (PAS) in all Norwegian somatic 
hospitals from 1994 (the year from which all hospitals 
adopted an electronic PAS) through 2009. A list of 
hospitals providing data can be found at 
www.cvdnor.no. An overview of the main diagnostic 
and procedural codes eligible for inclusion in 
CVDNOR is given in Table 1. For hospitalizations 
containing at least one eligible diagnosis or procedure 
code, all other diagnosis codes and procedure codes 
for that stay were also extracted. 
 A system called FS (Forskning i Sykehus = Re-
search in hospitals) developed by Tomislav Dimoski at 
the Norwegian Knowledge Centre for the Health Ser-
vices was used to extract the data retrospectively. The 
FS-system has been used in studies of other disease 
entities [15]. It can semi-automatically collect standar-
dized data on patient stays. Patients are identified by 
use of the Norwegian personal identification number 
(ID). Transfers between wards, departments or hospi-
tals for the same or different conditions in a patient can 
therefore be accounted for. A quality control compared 
FS system-extracted data with patients’ hospital 
records and found that 99% of the data were correct 
with regard to date and time of admission and main 
diagnosis [16]. 
 CVDNOR includes a unique ID-number for each 
patient and a unique code for each hospitalization. In 
addition, age at hospitalization, gender, municipality 
of residence, time and dates of hospitalization and dis-
charge (including transfers between wards and depart-
ments within the hospital), hospital, department and 
ward codes, main and secondary diagnoses (up to 20), 
medical procedure codes (up to 30) performed during 
the hospital stay, and information about type of hospi-
talization (acute or elective). Hospitalizations less than 
24 hours apart are merged and considered as one. 
 A more detailed report on CVDNOR data and qua-
lity issues will be published shortly at www.cvdnor.no. 
 
Cause of Death Register (www.ssb.no/dodsarsak_en) 
For all patients identified with a CVD or DM hospi-
talization and who later died, information about date of 
death, underlying and contributing cause(s) of death 
has been retrieved from the Cause of Death Registry. 
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In addition, information on individuals who died from 
CVD or DM but had no previous hospitalizations for 
CVD or DM was also obtained. Thus, CVDNOR 
contains data on all CVD or DM related deaths during 
the study period. 
 
Linkage of hospital data and cause of death data with 
other sources of information 
To increase the information obtained and broaden the 
field of potential research, a series of important linka-
ges have been made to other data sources including 
national registries. 
 
Statistics Norway, Population Register 
(www.ssb.no/english) 
Sociodemographic information includes marital status, 
personal and family income, country of birth, own 
education, education of spouse, and municipality. 
 
COhort of NORway (CONOR) (www.fhi.no/conor) 
Since the 1970’s, large regional health surveys with a 
focus on CVD and DM risk factors have been con-
ducted throughout Norway. These surveys were the 
starting point for the national research collaboration 
COhort of NORway (CONOR) [17], in which all 
Norwegian medical faculties (Tromsø, Trondheim, 
Bergen and Oslo), and the Norwegian Institute of 
Public Health participated. For the period 1992-2003, 
the number of participants in CONOR was 173 243, of 
whom 7460 participated twice. 
 The linkage of CONOR with CVDNOR provides 
the opportunity to study the impact of risk factors (e.g. 
health behaviours, anthropometry, health status) on 
CVD morbidity and mortality. In addition, changes in 
risk factors (in those individuals participating twice) 
and their impact on CVD occurrence may be examin-
ed. CONOR data have so far not been used for studies 
of CVD incidence due to the lack of nationwide mor-
bidity data. 
 
Other health surveys and clinical trials 
CVDNOR data will also be used as endpoints in 
several other health surveys including the Norwegian 
Counties Studies (www.fhi.no) and the Hordaland 
Health Studies (http://husk.b.uib.no). In addition, 
CVDNOR data will be used for extended follow-up of 
the randomized clinical trials NORVIT [18] and 
WENBIT [19]. 
 
Congenital malformations of the circulatory system, a 
CVDNOR substudy 
The hospital data also include information on congeni-
tal malformations of the circulatory system during the 
same time period. Epidemiologic studies of congenital 
malformations of the circulatory system have never 
been undertaken on a national level in Norway due to 
lack of data. This CVDNOR project will describe the 
epidemiology of congenital heart defects, such as exa-
mining national time trends, risk factors, and mortality 
of congenital heart defects in Norway. The project also 
ascertains information on congenital heart defects from 
the Medical Birth Registry of Norway and from the 
clinical database on congenital heart defects (Berte) at 
Oslo University Hospital. 
 
CVDCancer, a CVDNOR substudy 
The purpose of this project is to examine CVD oc-
currence in cancer survivors. It is known that patients 
who have been treated for cancer have an excess risk 
of developing CVD, compared to the population at 
large. In this project we link CVDNOR to the Nor-
wegian Cancer Registry to study the incidence of CVD 
in cancer patients compared to the general population. 
Through linkage to CONOR, risk factors for CVD 
among CONOR participants with and without cancer 
will be compared. 
 
Norwegian Prescription Database (www.norpd.no) 
There are plans to link to the Norwegian Prescription 
Database (NorPD), although this has not been done yet 
(as of March 2013). The NorPD contains data about 
dispensed drugs in Norway, and this linkage will pro-
vide the opportunity to examine use of specific medi-
cations in relation to incidence and prognosis of CVD 
and DM. It will also be used to better define disease 
entities, by exploring the medication use (such as dia-
betes medication to identify individuals with DM not 
hospitalized). 
 
Summary of data sources linked to CVDNOR  
Linkages between CVDNOR and other data sources 
will facilitate longitudinal epidemiologic studies of 
research questions otherwise not possible to answer. 
The linked datasets will provide the opportunity for fu-
ture research projects, and will be a valuable resource 
for epidemiologic studies. 
 
Data security  
Data from different sources are linked by Statistics 
Norway. The personal identification number (unique 
for each Norwegian resident) is replaced by a project 
specific and unique identification number (ID) before 
data files are forwarded to the University of Bergen. 
Data from the different sources are stored as separate 
datasets on a secure Windows server at the University 
of Bergen. The unique ID makes it possible to link the 
different data files. Researchers with given privileges 
may log on to the server via a ‘Remote Desktop’ solu-
tion. The Statistical packages SAS, SPSS, STATA and 
R are installed on the server in addition to standard 
software such as Microsoft Office. Data processing is 
usually done on the server. 
 Researchers are permitted access only to those data 
sources that are needed for each specific project. 
 
Ethical considerations and approvals  
The CVDNOR project, including the sub-project on 
congenital heart defects, was first approved by the 
Regional Committee for Medical and Health Research 
Ethics, Health Region West (036/09). Subsequently, 
the sub-study on CVDCancer has been approved (REK 
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Table 2.  An overview of CVDNOR hospitalizations and deaths 1994-2009. 
 
    Men  Women Total 
Number of patients, n (%)   640325 (48.7)   674692 (51.3) 1315057 
Age at time of hospitalization, mean (sd)        64.0 (19.0)       66.0 (21.3) 64.9 (20.2) 
Hospitalizations*, n (row %)    
    CVDNOR** 2270535 (53.2) 1996173 (46.8) 4266751 
    CVD 
    CHD 
1677554 (54.1) 1421295 (45.9) 3098849 
  750031 (61.1)   477909 (38.9) 1227940 
    AMI 
    PCI 
    Cerebrovascular disease 
    Diabetes mellitus 
    AF 
    Congenital malformations of the circulatory system 
  157230 (61.3)     99272 (38.7)   256502 
    59781 (74.7)     20291 (25.3)     80072 
  259102 (52.8)   231591 (47.2)   490693 
  340537 (53.4)   297208 (46.6)   637745 
  346490 (55.0)   282955 (45.0)   629445 
    27054 (51.0)     25985 (49.0)     53039 
Deaths    
    Deaths among CVDNOR hospitalized patients, n (% of patients) 
    CVD deaths among CVDNOR hospitalized patients, n (% of patients) 
    CVD deaths among persons not hospitalized in CVDNOR, 1994-2009 
  234059 (36.6)   236836 (35.1) 470895 (35.8) 
  104157 (16.3)   111090 (16.5) 215247 (16.4) 
31192 37331 68523 
* Hospitalizations less than 24 hours apart are merged. 
**Hospitalizations fulfilling the inclusion criteria described in Table 1.  
CVD – cardiovascular disease; CHD – coronary heart disease (ICD9: 410-414, ICD10: I20-25); AMI – acute myocardial infarction (ICD9: 
410, ICD10: I21,I22); PCI – percutaneous coronary interventions; AF – atrial fibrillation (ICD9: 427.3, ICD10: I48). 
 
 
 
Table 3.  Hospitalizations and deaths due to cardiovascular disease or diabetes mellitus among CONOR participants (1994-
2003). A CVDNOR project 1994-2009. 
 
CONOR participants Men Women Total 
Number of CONOR participants 84156 89087 173243 
Participants who died due to CVD, n (% ) 
Participants hospitalized with a CVD diagnosis after the CONOR survey, n (%) 
Participants hospitalized with a DM diagnosis after the CONOR survey, n (% )  
 5139 (5.9) 3918 (4.2) 9057 (5.0) 
24698 (29.0) 19421 (21.8) 44118 (25.5) 
4313 (5.1) 3262 (3.7) 7575 (4.4) 
CONOR – Cohort of NORway; CVD – cardiovascular disease; DM – diabetes mellitus. 
 
 
2009/861-19), as has linkages to the Hordaland Health 
Studies (REK 2009/825), the Norwegian Counties 
studies 1974-88 (REK 2012/827), and the clinical 
trials NORVIT-WENBIT (REK 2010/1880). 
 
 
PRELIMINARY RESULTS 
 
During the study period 1994-2009, 1315057 persons 
(51.3% women) contributing with 4266751 hospitali-
zations (46.8% among women) fulfilled the inclusion 
criteria listed in Table 1. 
 A total of 68523 patients died from CVD without 
being hospitalized during the same period (Table 2). 
Mean (SD) age for hospitalized patients was 64.9 
(20.2) years. Women were older than men at the time 
of hospitalization. A coronary heart disease (CHD) 
diagnosis code was found in 1/3 of the hospitalizations 
as main or secondary diagnosis. A DM diagnosis code 
was found in 15% and a cerebrovascular disease diag-
nosis code in 10% of all hospitalizations, and an atrial 
fibrillation diagnosis code was found in 14.8%. During 
the study period, 35.8% of patients who had a 
CVDNOR hospitalization died. Of these, 45.7% had a 
CVD related code as the underlying cause of death and 
63.2% had a CVD related code mentioned on the death 
certificate. In CVDNOR, 53039 (4%) patients were re-
gistered with a congenital heart defect code. 
 Table 3 summarizes the events (hospitalizations and 
deaths) for CONOR participants after participation in 
the health survey. Among all CONOR participants, 
25.5% had at least one CVD hospitalization and 5% 
died due to CVD. During follow up, 4.4% of CONOR 
participants had a hospitalization during which DM 
was coded as main or secondary diagnosis. 
 Additional information regarding marital status, re-
sidence, country of birth and education for patients 30 
years and older included in CVDNOR at their first 
hospitalization is given in Table 4. Those individuals 
who did not match with the Population Registry 
(28357 individuals; 16226 men and 12091 women) are 
excluded from the table. 
 Almost half of the patients were married and 52% 
lived in the South-East region, versus 10% in the 
North region. The majority of patients (92.4%) were 
born in Norway. Only 1.3% was born in another Nor-
dic country and the remainder (6.3%) elsewhere. Some 
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Table 4.  Socio-demographic data for patients 30 years and older at first hospitalization registered in CVDNOR and 
with match to the Population Registry: a CVDNOR project 1994-2009. 
 
Patients with a CVDNOR diagnosis or procedure            Men      Women      Total 
Number of patients, n (%) 570 428   585 171   1 155 599 
Marital status*, n (%)      
     Married 
     Widow(er) 
     Divorced/separated 
     Unmarried 
     Missing 
369 111(64.7)  263 507 (45.0)  632 618 (54.7) 
52 897 (9.3)  191 791 (32.8)  244 688 (21.2) 
66 502 (11.7)  64 949 (11.1)  131 451 (11.4) 
78 987 (13.9)  62 636 (10.7)  141 623 (12.3) 
2931 (0.5)  2 288 (0.4)  5219 (0.5) 
Residence by health region n (%)      
     South-East 
     West 
     Mid 
     North 
     Missing  
312249 (54.7)  324409 (55.4)  636658 (55.1) 
110609 (19.4)  113482 (19.4)  224091 (19.4) 
81248 (14.2)  82365 (14.1)  163613 (13.5) 
63382 (11.1)  62621 (10.7)  137919 (14.2) 
2940 (0.5)  2294 (0.4)  5234 (0.5) 
Country of birth n (%)      
     Norway 
     Nordic countries outside Norway 
     Europe outside Nordic countries 
     Outside Europe 
     Missing 
540 853 (94.8)  553 666 (94.6)  1 094 519 (94.7) 
7 502 (1.3)  8 083 (1.4)  15585 (1.4) 
9 958 (1.8)  9 933 (1.7)  19891 (1.7) 
12 053 (2.1)  13 406 (2.3)  25459 (2.2) 
62 (0.0)  83 (0.0)  145 (0.0) 
Education n (%)**      
     Basic or no education 
     Upper secondary education 
     Tertiary education, short 
     Tertiary education, long 
     Missing 
210 063 (36.8)  271 051 (46.3)  481 114 (41.6) 
254 005 (44.5)  220 243 (37.6)  474 248 (41.0) 
60 663 (10.6)  67 832 (11.6)  128 495 (11.1) 
29 644 (5.2)  10 070 (1.7)  39714 (3.4) 
16 053 (2.8)  15 975 (2.7)  32 028 (2.8) 
* Marital status the year of the first hospitalization or the year before if missing. 
** Maximum achieved education the year before the first hospitalization. 
 
 
 
75.7% had upper secondary education or less. 
 Figure 1 presents trends in hospitalizations with a 
CVD or DM related diagnosis or CVD procedure du-
ring the study period. Hospitalization rates per 100000 
inhabitants are age-standardized using the Nordic 
population in the year 2000 as standard population. 
Both the number of hospitalizations and age adjusted 
rates increased from 1994 to 2006 and levelled off or 
even decreased thereafter. 
 The CVDNOR data became available for analysis 
around mid-2012. Our first objective was to investi-
gate trends of acute myocardial infarction (AMI) 
incidence rates, by sex and age groups (Sulo et al, 
submitted; abstract presented at EuroPrevent, Rome, 
April 2013). Overall, age standardized incidence rates 
decreased during 2001-2009. However, among younger 
adults (<45 years), rates of hospitalization for incident 
AMI increased over time. Other on-going analyses 
include trends in survival after AMI, trends in AMI 
event rates and recurrences and association between 
education level and survival after AMI (two abstracts 
accepted to ESC 2013, Amsterdam). 
 
How can CVDNOR data be accessed?  
Information on how to apply for access to CVDNOR 
data can be found on the study website www.cvdnor.no. 
Strength and weaknesses 
 
CVDNOR is a large dataset covering the whole po-
pulation of Norway. As such it is not influenced by 
selection bias. However, as in other registry-based 
information, details on risk factors, severity of the 
disease, medication use and other clinical information 
is missing. Because patients with less severe forms of 
CVD or DM are not always hospitalised (or die), the 
estimates based on CVDNOR data will underestimate 
the true occurrence of these conditions. However, by 
linkages to the prescription registry, information on the 
true incidence of medically treated diseases like DM 
will likely be obtained. 
 
 
ACKNOWLEDGEMENTS 
 
The CVDNOR project has received economic support 
from Nasjonalforeningen for folkehelsen. The authors 
thank Tomislav Dimoski at The Norwegian Knowledge 
Centre for the Health Services, Oslo, Norway for his 
contribution by developing software necessary for 
obtaining data from Norwegian hospitals, conducting 
the data collection and quality assurance of data in this 
project. 
106  G. SULO ET AL. 
 
Figure 1.  Trends in hospitalizations with a cardiovascular (CVD) or diabetes mellitus (DM) related diagnosis 
or CVD procedure, 1994-2009. 
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